Back to top
more

Spero Therapeutics (SPRO)

(Delayed Data from NSDQ)

$1.32 USD

1.32
220,595

+0.01 (0.76%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $1.32 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Gilead (GILD) Gets FDA Nod for Veklury for Hepatic Impairment

by Zacks Equity Research

Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.

Bristol Myers' (BMY) Opdivo Gets EC Nod for Label Expansion

by Zacks Equity Research

Bristol Myers (BMY) obtains approval in the EU for Opdivo for the adjuvant treatment of adults and adolescents with stage IIB or IIC melanoma who have undergone complete resection.

Down -11.72% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Spero Therapeutics, Inc. (SPRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Gilead's (GILD) Leukemia Study Progress Put on Clinical Hold

by Zacks Equity Research

Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.

Novartis (NVS) Plans to Spin-Off Sandoz in Early October

by Zacks Equity Research

Novartis (NVS) progresses with the proposed spin-off of its Sandoz arm (scheduled for early October) and invites shareholders for a meeting on the same.

Regeneron's (REGN) Application for Blood Cancer Drug Accepted

by Zacks Equity Research

Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma gets accepted for review in the EU.

Bristol Myers (BMY) Announces Positive Updated NSCLC Data

by Zacks Equity Research

Bristol Myers' (BMY) repotrectinib shows durable efficacy benefits in patients with locally advanced or metastatic ROS1-Positive non-small cell lung cancer.

Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies

by Zacks Equity Research

Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.

Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%

by Zacks Equity Research

Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company will instead focus on its hunTR TCR discovery platform and explore broad strategic alternatives.

Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 20.69% and 23.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 4.11% and 77.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 89.47% and 42.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of 4.29% and 18.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in TELA Bio, Inc. (TELA): Can Its 11.4% Jump Turn into More Strength?

by Zacks Equity Research

TELA Bio, Inc. (TELA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Bausch (BHC) Gains on Court Ruling for Xifaxan Against Norwich

by Zacks Equity Research

Bausch (BHC) obtains a positive ruling for one of its top drugs, Xifaxan, against Norwich from the U.S. District Court of Delaware. Stock up in response to the same.

Intercept (ICPT) Gains 26.2% YTD: What's in Store?

by Zacks Equity Research

Intercept (ICPT) has been having a good run in the year so far, but investors are wary ahead of the upcoming advisory meeting by the FDA's Gastrointestinal Drugs Advisory Committee to review its NDA seeking approval of OCA in steatohepatitis (NASH).

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 28.57% and 3.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y

by Zacks Equity Research

Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.

bluebird (BLUE) Posts Q1 Earnings, Focuses on Zynteglo, Skysona

by Zacks Equity Research

bluebird bio (BLUE) delivers earnings of 21 cents per share in the first quarter, due to a one-time gain. Revenues increase year over year.

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -61% and 67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) Tops Q1 Earnings & Sales, Reiterates '23 View

by Zacks Equity Research

Perrigo (PRGO) reports encouraging first-quarter 2023 results. Management reaffirms the financial guidance for 2023. The company's current CEO announces plans to retire by the end of July.

Viatris (VTRS) Q1 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.

Bausch Health's (BHC) Q1 Earnings & Sales Miss, Shares Down

by Zacks Equity Research

Bausch (BHC) declines as it misses on earnings and sales in the first quarter.

Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q1

by Zacks Equity Research

Karuna Therapeutics (KRTX) reports encouraging first-quarter 2023 results. The company beats estimates for earnings and sales.

Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) reports encouraging first-quarter results, beating estimates for earnings and sales.